Study of Ifinatamab Deruxtecan and Pembrolizumab, With or Without Chemotherapy, for Patients With Untreated Advanced Esophageal Cancer

1 1 1 1

What is this study about?

This clinical trial is focused on studying treatments for esophageal cancer, specifically a type called esophageal squamous cell carcinoma. The study will explore the effects of combining different treatments, including a new drug called Ifinatamab Deruxtecan and an existing medication known as Pembrolizumab (also referred to by its code name MK-3475). Some participants may also receive additional chemotherapy drugs, such as Oxaliplatin, Fluorouracil, and Calcium Folinate.

The purpose of the study is to evaluate the safety and tolerability of these treatment combinations and to determine the best dose for the new drug. Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor how well the treatments work and how the body responds to them over time. This includes looking at how long the treatment effects last, how the disease progresses, and overall survival rates.

Throughout the study, researchers will also measure the levels of Ifinatamab Deruxtecan in the blood to understand how the drug is processed by the body. The study aims to provide valuable information on the effectiveness and safety of these treatment combinations for people with advanced esophageal cancer.

1 joining the study

Upon joining the study, participants will be informed about the trial’s purpose, procedures, and potential risks and benefits. Consent will be obtained to ensure understanding and agreement to participate.

2 initial assessment

Participants will undergo an initial assessment to confirm eligibility. This includes verifying the diagnosis of locally advanced unresectable or metastatic squamous cell carcinoma of the esophagus and ensuring measurable disease is present.

3 treatment phase

Participants will receive a combination of investigational agents. The main medications include ifinatamab deruxtecan and pembrolizumab, both administered through intravenous infusion. The specific dosage and frequency will be determined by the study protocol.

Some participants may also receive chemotherapy, which could include oxaliplatin, calcium folinate, and fluorouracil, all administered via intravenous infusion. The exact regimen will depend on the study group assignment.

4 monitoring and follow-up

Throughout the trial, participants will be closely monitored for any side effects or adverse reactions. Regular follow-up visits will be scheduled to assess the treatment’s effectiveness and participant well-being.

Participants will undergo various tests and assessments, including imaging studies, to evaluate the response to treatment and adjust the regimen if necessary.

5 end of treatment

At the end of the treatment phase, participants will have a final assessment to determine the overall response to the investigational agents. This includes evaluating the duration of response and progression-free survival.

Participants will be informed about the next steps, which may include continued monitoring or additional treatment options based on the study’s findings.

Who Can Join the Study?

The patient must have a confirmed diagnosis of esophageal squamous cell carcinoma, which is a type of cancer in the esophagus.
The cancer must be in a stage that is locally advanced, cannot be removed by surgery, or has spread to other parts of the body.
The patient must have measurable disease, meaning the cancer can be measured by medical imaging tests. If the cancer was previously treated with radiation, it must show signs of growth to be considered measurable.
The patient must have side effects from previous cancer treatments that are mild (Grade 1) or have returned to the level they were before treatment. Exceptions are hair loss and skin color changes, which are not considered. Hormone-related side effects must be well-managed with medication, and nerve-related side effects must be mild (Grade 2) or less.
The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, which means they are fully active or have some symptoms but do not need bed rest during the day.
The patient must be within the age range of adults, as specified by the trial.
Both male and female patients are eligible to participate.

Who Cannot Join the Study?

Patients with any other type of cancer besides esophageal squamous cell carcinoma cannot participate.
Patients who are not within the specified age range cannot participate.
Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups like children, pregnant women, or those unable to give consent.
Patients who have not recovered from previous treatments or surgeries cannot participate.
Patients with severe or uncontrolled medical conditions cannot participate. This includes conditions like uncontrolled high blood pressure or heart disease.
Patients who are currently participating in another clinical trial cannot participate.
Patients who have had a severe allergic reaction to similar treatments in the past cannot participate.
Patients who are pregnant or breastfeeding cannot participate.
Patients who have an active infection that requires treatment cannot participate.
Patients with a history of drug or alcohol abuse that could interfere with the study cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Technische Universitaet Dresden	Dresden	Germany
Oslo Universitetssykehus HF	Oslo	Norway
Haematologisch Onkologische Praxis Eppendorf	Hamburg	Germany
Universitaetsklinikum Heidelberg AöR	Heidelberg	Germany
Centre Hospitalier Universitaire De Lille	Lille	France
Centre Hospitalier Regional Et Universitaire De Brest	Brest	France

Other Sites

Site Name	City	Country
Istituto Oncologico Veneto	Padua	Italy
Masarykuv Onkologicky Ustav	Brno-Stred	Czechia
Ospedale San Raffaele S.r.l.	Milan	Italy
Hopital Beaujon	Clichy	France
Uvwqdgzlgeppbzcoldnyc Dwekatleuth Auy	Duesseldorf	Germany

Trial status

Country	Status	Recruitment Start
Czechia	Recruiting	18.08.2025
France	Recruiting	18.08.2025
Germany	Recruiting	18.08.2025
Italy	Recruiting	18.08.2025
Norway	Recruiting	18.08.2025

Trial locations

Investigated drugs:

Pembrolizumab is a type of medication known as an immunotherapy. It works by helping your immune system fight cancer cells. Pembrolizumab blocks a specific protein on the surface of cancer cells, which allows your immune system to better recognize and attack these cells. This medication is used in the trial to see if it can help treat esophageal cancer when used alone or in combination with other treatments.

Investigated diseases:

Oesophageal squamous cell carcinoma

Esophageal squamous cell carcinoma – This is a type of cancer that forms in the squamous cells lining the esophagus, which is the tube that carries food from the throat to the stomach. It typically begins in the upper and middle parts of the esophagus. As the disease progresses, it can cause difficulty swallowing, weight loss, and chest pain. The cancer may spread to nearby lymph nodes and other organs. Over time, it can lead to narrowing of the esophagus, making it hard to swallow solid foods. The progression of the disease can vary, and it often requires medical evaluation to understand its development.

Trial ID:

2024-514273-22-00

Protocol code:

MK-3475-06E

Trial Phase:

Human Pharmacology (Phase I) – Other

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of Ifinatamab Deruxtecan and Pembrolizumab, With or Without Chemotherapy, for Patients With Untreated Advanced Esophageal Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?